Phage technology rolls-out possible control for food poisoning

University of Nottingham experts have collaborated with the Canadian biotech company GangaGen Life Sciences Inc. to develop bacteriophage-based treatments for the control of Campylobacter. Campylobacter is a bacterial intestinal disease characterized by vomiting, diarrhea and fever. The research implements phage technology for preventing food contamination from pathogenic bacteria in animal products. “GangaGen has demonstrated in production animal trials that we can isolate and use phages with full regard for safety, and that are benign to animals, humans and the environment,” said Dr Rainer Engelhardt, chief executive of GangaGen Life Sciences Inc.

Researchers from the National Institute of Allergy and Infectious Diseases have reported that a combination therapy with three classes of antiretroviral drugs could possibly reduce HIV in people with an existing low viral count. Research evaluated seven HIV-positive people for 3.5 to 4.5 years, keeping a count on the resting CD4+ T cells in which HIV remained throughout treatment. Research showed that early treatment with the three-drug combination therapy reduced the number of infected resting T cells by 50% every 4.6 months. Inferences from the research showed that 7.7 years of the combination therapy in the early stages of HIV could facilitate complete elimination of the HIV virus.

Researchers at the Virginia Commonwealth University Medical Center have declared the capacity of the drug peginterferon (pegylated interferon alfa-2a) for curing Hepatitis C. The study showed peginterferon either alone, or in combination with ribavirin, could cure Hepatitis C. The study was presented at the 38th annual Digestive Disease Week conference in Washington. The study involved six months of drug therapy for patients suffering from Hepatitis C. Tests following the drug therapy showed positive results, as 50 % of the patients tested negative for Hepatitis C.

Powered by Qumana

Comments

[moncler outlet]

you will find that it worth paid. Come on and join us.